- Home
- CIK vs MSLE Comparison
CIK vs MSLE Comparison
Compare CIK & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CIK | MSLE |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.1M | 146.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIK | MSLE |
|---|---|---|
| Price | $2.58 | $6.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 399.4K | 109.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $5.50 |
| 52 Week High | $3.01 | $13.39 |
Technical Indicators
Market Signals| Indicator | CIK | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 37.82 |
| Support Level | $2.44 | $5.50 |
| Resistance Level | $3.00 | $7.52 |
| Average True Range (ATR) | 0.04 | 0.59 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 77.65 | 44.55 |
Price Performance
Historical ComparisonAbout CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.